Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma

A Phase II Study of Velcade and Temsirolimus for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

The investigators want to find out if the drugs Velcade and temsirolimus given together are effective in treating cancer. Velcade and temsirolimus are each FDA approved individually for certain types of cancer (Velcade for multiple myeloma and mantle cell lymphoma, and temsirolimus for renal cell carcinoma) but are not currently approved in combination for B-cell non-Hodgkin lymphoma. The investigators are trying to find out if giving these 2 drugs together will improve the period of time that the patient's cancer is stopped or slowed from growing and causing symptoms.

Study Overview

• Status: Completed
• Conditions: Non-Hodgkins Lymphoma
• Intervention / Treatment: Drug: Velcade; Drug: Temsirolimus

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • South Dakota
    • Rapid City, South Dakota, United States, 57701
      • Rapid City Regional Hospital John T. Vucurevich Cancer Care Institute
  • Wisconsin
    • Green Bay, Wisconsin, United States, 54143
      • Aurora Baycare Medical Center-GreenBay
    • Green Bay, Wisconsin, United States, 54301
      • St Vincent Regional Cancer Center CCOP
    • Green Bay, Wisconsin, United States, 54313
      • Bellin Memorial Hospital, Inc
    • La Crosse, Wisconsin, United States, 54601
      • Gunderson Lutheran Health System
    • Madison, Wisconsin, United States, 53715
      • UW Health Oncology- 1 S Park
    • Madison, Wisconsin, United States, 53792
      • University of Wisconsin Cancer Center
    • Marinette, Wisconsin, United States
      • Aurora BayCare Medical Center
    • Marshfield, Wisconsin, United States, 54449
      • Marshfield Clinic
    • Milwaukee, Wisconsin, United States, 53226
      • Medical College of Wisconsin
    • Milwaukee, Wisconsin, United States, 53211
      • Columbia St Mary's, Inc
    • Sheboygan, Wisconsin, United States, 53081
      • Aurora Sheboygan Memorial Medical Center
    • Summit, Wisconsin, United States, 53066
      • Aurora Medical Center in Summit
    • Two Rivers, Wisconsin, United States, 54241
      • Aurora Medical Center in Two Rivers
    • Waukesha, Wisconsin, United States, 53188
      • Waukesha Memorial Hospital
    • Wausau, Wisconsin, United States, 54401
      • Aspirus Wausau Hospital
    • Wauwatosa, Wisconsin, United States, 53226
      • Aurora Health Care Metro, Inc.
    • Wisconsin Rapids, Wisconsin, United States, 54494
      • UW Cancer Center-Riverview

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Relapsed or refractory B-cell non-Hodgkin lymphoma which includes: diffuse large B-cell lymphoma; primary mediastinal large B-cell lymphoma; follicular lymphoma (grade 1, 2 or 3); mantle cell lymphoma; small lymphocytic lymphoma; marginal zone lymphoma; lymphoplasmacytic lymphoma; B-cell lymphoblastic lymphoma; or Burkitt lymphoma. "Grey-zone" lymphomas must be approved by the Wisconsin Oncology Network (WON) Study Chair or Principal Investigator prior to enrollment.
• At least one measurable tumor mass (>1.5 cm in the long axis and > 1.0 cm in the short axis) that has not been previously irradiated, or has grown since previous irradiation.
• Documented relapse or progression following prior antineoplastic therapy.
• No clinical or documented radiographic evidence of central nervous system lymphoma.
• Eastern Cooperative Oncology Group [ECOG] performance status of 0-2.
• The following clinical laboratory values within 14 days prior to enrollment:
• Absolute neutrophil count (ANC) ≥ 1.5 x 109 cells / L
• Platelets ≥ 100 x 109 cells / L
• Alanine transaminase (ALT) and Aspartate transaminase (AST) ≤ 3X the upper limit of normal (ULN)
• Total bilirubin ≤ 2X the upper limit of normal (ULN).
• Calculated creatinine clearance ≥40 mL/min (using the Cockcroft-Gault equation).
• Female subjects must be either post-menopausal for at least 1 year or surgically sterilized, agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of Velcade, or agree to completely abstain from heterosexual intercourse.
• Male subjects, even if surgically sterilized (ie, status postvasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse.

Exclusions:

• Antineoplastic, experimental, or radiation therapy within 14 days prior to enrollment, or 21 days prior to Day 1 of Cycle 1.
• Radioimmunoconjugates within 10 weeks of Day 1 of Cycle 1.
• Autologous stem cell transplant within 3 months before Day 1 of Cycle 1, or any prior history of allogeneic stem cell transplant.
• Platelet transfusion within 7 days of Day 1 of Cycle 1.
• Ongoing therapy with glucocorticoids. Prednisone ≤15 mg per day or its equivalent is allowed.
• Patient has Grade 2 or greater peripheral neuropathy within 14 days before enrollment.
• Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
• Patient has hypersensitivity to Velcade, boron or mannitol.
• Female subjects that are pregnant or breast-feeding.
• Serious medical or psychiatric illness that is likely to interfere with participation
• Diagnosed or treated for another malignancy within 2 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
• Prior therapy with both Velcade and temsirolimus. Patients who have previously been treated with either Velcade or temsirolimus (but not both) are eligible.
• Radiation therapy within 3 weeks before randomization.
• Patients must not be taking the following strong CyP3A inducers at study entry: phenytoin, phenobarbital, rifampin, carbamazepin, rifabutin, rifampicin, a one week washout period is required.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Velcade plus Temsirolimus; Velcade 1.6 mg/m2 weekly (days 1, 8, 15, and 22) Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29) Treat for up to 6 cycles, cycles are 35 days long.	Drug: Velcade; Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22); Other Names: bortezomib, PS-341; Drug: Temsirolimus; Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29); Other Names: Torisel

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Response Rate	The primary objective of this study is to determine whether Velcade in combination with temsirolimus provides benefit to subjects with relapsed or refractory B-cell non-Hodgkin lymphoma as assessed by overall response rate (ORR) to therapy. ORR is the sum of patients with a Complete Response and Partial Response to therapy. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete REsponse (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.	Up to 60 months
Progression Free Survival	The primary objective of this study is to determine whether Velcade in combination with temsirolimus provides benefit to subjects with relapsed or refractory B-cell non-Hodgkin lymphoma as assessed by progression-free survival (PFS).	Up to 60 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety of This Regimen	Safety of the regimen will be measured by frequency and severity of adverse events.	Up to 36 months
Complete Response Rate	The complete response rate (CR) to therapy as defined by International Lymphoma Response Criteria.	Up to 60 months
Tolerability of the Regimen	Tolerability of the regimen is measured by the number of subjects able to complete the therapy as planned.	Up to 36 months
Duration of Response	Duration of Response is how long a response to therapy is held before a subject has progressive disease.	Up to 60 months
Overall Survival	Length of time from enrollment until death.	Up to 60 months

Collaborators and Investigators

• Sponsor: University of Wisconsin, Madison
• Collaborators: National Cancer Institute (NCI); Pfizer; Millennium Pharmaceuticals, Inc.
• Investigators: Principal Investigator: Brad S Kahl, MD, Universtity of Wisconsin- Madison; Study Chair: Timothy S Fenske, MD, Medical College of Wisconsin

Study record dates

Study Major Dates

• Study Start: February 1, 2011
• Primary Completion (Actual): October 1, 2013
• Study Completion (Actual): June 1, 2014

Study Registration Dates

• First Submitted: January 20, 2011
• First Submitted That Met QC Criteria: January 21, 2011
• First Posted (Estimate): January 24, 2011

Study Record Updates

• Last Update Posted (Actual): December 13, 2019
• Last Update Submitted That Met QC Criteria: December 11, 2019
• Last Verified: July 1, 2017

More Information

Terms related to this study

• Keywords: non-hodgkins lymphoma; velcade; temsirolimus
• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma; Lymphoma, Non-Hodgkin; Physiological Effects of Drugs; Anti-Infective Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antifungal Agents; Bortezomib; Sirolimus
• Other Study ID Numbers: HO10407; A534260 (Other Identifier: UW Madison); SMPH\MEDICINE\HEM-ONC (Other Identifier: UW Madison); H-2010-0393 (Other Identifier: IRB); NCI-2011-00647 (Registry Identifier: NCI Trial ID)